RLYB News and Press, Rallybio Corporation From 06/29/23

-- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patient...

-- RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achie...

2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...

-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH -- -- Company to Host Webcast Following ISTH Oral Presentation of RLYB212 -- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to i...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Company management will participate in a fireside chat at the Jeffe...

-- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 -- -- Phase 1 Mul...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the JMP S...

2023-04-10 09:21:27 ET Shares of Rallybio Corporation ( NASDAQ: RLYB ) gained ~9% pre-market Monday after Wedbush initiated its coverage with an Outperform rating and a $17 price target citing its lead program RLYB212 and the potential of its management. "Simply put, we se...

2023-04-10 08:55:07 ET OncoSec Medical ( ONCS ) +65%.GlucoTrack ( GCTK ) +29%.Guardforce AI ( GFAI ) +22%.Eloxx Pharmaceuticals ( ELOX ) +15%.Cocrystal Pharma ( COCP ) +13% on completing $4 Million private placement priced at-the-market under Nasdaq rules.Enlivex Therape...

-- Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT -- -- In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a Monoclonal Anti-HPA-1a Antibody, in the First Quarter of 2023 -- Rallybio Corpo...